Aerovance, a developer of asthma medications, has received $38 million in a post-recapitalized third round of financing, VentureBeat said.
The round, which gives the company $20 million up front, with the option of claiming the remaining $18 million as necessary, was led by ProQuest Investments. Other investors included BB Biotech Ventures, Alta Partners and Apax Partners.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment